ME02181B - Ne-nukleozidni inhibitori reverzne transkriptaze - Google Patents

Ne-nukleozidni inhibitori reverzne transkriptaze

Info

Publication number: ME02181B
Authority: ME; Montenegro
Prior art keywords: alkyl; independently; haloalkyl; cycq; halogen
Prior art date: 2010-03-30

Application number

MEP-2015-76A

Other languages

English (en)

Unknown language (me)

Inventor

Jason Burch

Bernard Cote

Natalie Nguyen

Chun Sing Li

Miguel St-Onge

Danny Gauvreau

Original Assignee

Merck Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-30

Filing date

2011-03-28

Publication date

2015-10-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02181(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-03-28 Application filed by Merck Canada Inc filed Critical Merck Canada Inc

2015-10-20 Publication of ME02181B publication Critical patent/ME02181B/me

Links

229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 title 1
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 title 1
229910052799 carbon Inorganic materials 0.000 claims 25
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 22
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 22
150000001875 compounds Chemical class 0.000 claims 19
229910052736 halogen Inorganic materials 0.000 claims 17
150000002367 halogens Chemical class 0.000 claims 17
125000001424 substituent group Chemical group 0.000 claims 17
125000000217 alkyl group Chemical group 0.000 claims 14
229910052757 nitrogen Inorganic materials 0.000 claims 14
150000003839 salts Chemical class 0.000 claims 13
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 8
229910052739 hydrogen Inorganic materials 0.000 claims 8
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 7
125000005842 heteroatom Chemical group 0.000 claims 6
238000011321 prophylaxis Methods 0.000 claims 6
238000011282 treatment Methods 0.000 claims 6
125000003118 aryl group Chemical group 0.000 claims 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
229910052717 sulfur Inorganic materials 0.000 claims 5
125000003709 fluoroalkyl group Chemical group 0.000 claims 4
229910052760 oxygen Inorganic materials 0.000 claims 4
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
208000030507 AIDS Diseases 0.000 claims 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
208000031886 HIV Infections Diseases 0.000 claims 3
208000037357 HIV infectious disease Diseases 0.000 claims 3
125000000753 cycloalkyl group Chemical group 0.000 claims 3
125000001072 heteroaryl group Chemical group 0.000 claims 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
229920006395 saturated elastomer Polymers 0.000 claims 3
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
101100273648 Mus musculus Ccna2 gene Proteins 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
125000001624 naphthyl group Chemical group 0.000 claims 2
125000006574 non-aromatic ring group Chemical group 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 1
125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 1
DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
125000002619 bicyclic group Chemical group 0.000 claims 1
125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 claims 1
125000004122 cyclic group Chemical group 0.000 claims 1
125000000392 cycloalkenyl group Chemical group 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 1
125000000623 heterocyclic group Chemical group 0.000 claims 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

MEP-2015-76A 2010-03-30 2011-03-28 Ne-nukleozidni inhibitori reverzne transkriptaze ME02181B (me)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US31882410P	2010-03-30	2010-03-30
US32157310P	2010-04-07	2010-04-07
EP11761856.1A EP2552902B1 (en)	2010-03-30	2011-03-28	Non-nucleoside reverse transcriptase inhibitors
PCT/CA2011/000320 WO2011120133A1 (en)	2010-03-30	2011-03-28	Non-nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number	Publication Date
ME02181B true ME02181B (me)	2015-10-20

Family

ID=44710363

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MEP-2015-76A ME02181B (me)	2010-03-30	2011-03-28	Ne-nukleozidni inhibitori reverzne transkriptaze
MEP-2016-282A ME02570B (me)	2010-03-30	2011-03-28	Farmaceutska kompozicija koja sadrži ne-nukleozidni inhibitor reverzne transkriptaze

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MEP-2016-282A ME02570B (me)	2010-03-30	2011-03-28	Farmaceutska kompozicija koja sadrži ne-nukleozidni inhibitor reverzne transkriptaze

Country Status (44)

Country	Link
US (2)	US8486975B2 (2)
EP (2)	EP2552902B1 (2)
JP (2)	JP5281718B2 (2)
KR (1)	KR101421861B1 (2)
CN (1)	CN102971308B (2)
AR (1)	AR080859A1 (2)
AU (1)	AU2011235568B2 (2)
BR (1)	BR112012024691B1 (2)
CA (1)	CA2794377C (2)
CL (1)	CL2012002744A1 (2)
CO (1)	CO6630126A2 (2)
CR (1)	CR20120503A (2)
CY (3)	CY1118774T1 (2)
DK (2)	DK2552902T3 (2)
DO (1)	DOP2012000256A (2)
EA (1)	EA024804B1 (2)
EC (1)	ECSP12012201A (2)
ES (2)	ES2609636T3 (2)
FI (1)	FIC20190021I1 (2)
GE (1)	GEP20156368B (2)
HN (1)	HN2012002039A (2)
HR (2)	HRP20150427T1 (2)
HU (4)	HUE025336T2 (2)
IL (2)	IL222030A (2)
LT (3)	LT2924034T (2)
LU (2)	LUC00113I9 (2)
MA (1)	MA34170B1 (2)
ME (2)	ME02181B (2)
MX (1)	MX2012011379A (2)
MY (1)	MY163979A (2)
NI (1)	NI201200146A (2)
NL (1)	NL300980I2 (2)
NO (2)	NO2019019I1 (2)
NZ (1)	NZ602670A (2)
PE (1)	PE20130158A1 (2)
PH (1)	PH12012501923A1 (2)
PL (2)	PL2552902T3 (2)
PT (2)	PT2552902E (2)
RS (2)	RS54017B1 (2)
SG (1)	SG184347A1 (2)
SI (2)	SI2924034T1 (2)
TN (1)	TN2012000455A1 (2)
TW (1)	TWI458719B (2)
WO (1)	WO2011120133A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2924034T1 (sl) *	2010-03-30	2017-05-31	Merck Canada Inc.	Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
CA2882947A1 (en)	2012-09-26	2014-04-03	Merck Sharp & Dohme Corp.	Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
BR112015012843B8 (pt)	2012-12-05	2023-04-25	Merck Sharp & Dohme	Método para sintetizar o composto
US20160287568A1 (en) *	2013-11-22	2016-10-06	Merck Sharp & Dohme Corp.	Composition of a non-nucleoside reverse transcriptase inhibitor
CA2930585A1 (en) *	2013-12-04	2015-06-11	Merck Sharp & Dohme Corp.	Process for making reverse transcriptase inhibitors
WO2015153304A1 (en)	2014-04-01	2015-10-08	Merck Sharp & Dohme Corp.	Prodrugs of hiv reverse transcriptase inhibitors
US10301624B2 (en)	2014-06-25	2019-05-28	The General Hospital Corporation	Targeting human satellite II (HSATII)
WO2017095761A1 (en)	2015-12-02	2017-06-08	Merck Sharp & Dohme Corp.	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
US11077050B2 (en)	2017-03-24	2021-08-03	Merck Sharp & Dohme Corp.	Formulation for parenteral administration
RU2019136678A (ru)	2017-04-18	2021-05-18	Сипла Лимитед	Комбинированная терапия для применения в лечении ретровирусных инфекций
JP2021512956A (ja)	2018-02-06	2021-05-20	ザジェネラルホスピタルコーポレイション	腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ
EP3823632B1 (en) *	2018-07-17	2025-10-29	Merck Sharp & Dohme LLC	Efda in combination with doravirine for use in treating f227c mutated hiv infections
CA3122571C (en)	2018-12-18	2023-08-01	Merck Sharp & Dohme Corp.	Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
CN110801455B (zh) *	2019-11-12	2020-06-02	河北医科大学第二医院	用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) *	2021-12-27	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体的制备方法
CN114349690B (zh) *	2022-02-15	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体合成方法
CN116903590A (zh) *	2023-06-06	2023-10-20	延边大学	一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) *	2023-12-15	2025-06-17	山东诚创蓝海医药科技有限公司	多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904045D0 (sv)	1999-11-09	1999-11-09	Astra Ab	Compounds
TW200423930A (en) *	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
BRPI0408704A (pt)	2003-03-24	2006-03-07	Hoffmann La Roche	benzil-piridazinonas como inibidores de transcriptase reversa
TW200505441A (en)	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
US7166738B2 (en)	2004-04-23	2007-01-23	Roche Palo Alto Llc	Non-nucleoside reverse transcriptase inhibitors
DE602005017604D1 (de)	2004-04-23	2009-12-24	Hoffmann La Roche	Inhibitoren der nicht-nukleosid-inhibitoren der reversen transkriptase
CA2592092A1 (en)	2004-12-22	2006-06-29	Pfizer Limited	Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es)	2005-07-22	2007-12-05	Merck & Co Inc	Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
WO2007045573A1 (en)	2005-10-19	2007-04-26	F. Hoffmann-La Roche Ag	Phenyl-acetamide nnrt inhibitors
AU2006303367A1 (en)	2005-10-19	2007-04-26	F. Hoffmann-La Roche Ag	N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
TW200831085A (en)	2006-12-13	2008-08-01	Merck & Co Inc	Non-nucleoside reverse transcriptase inhibitors
CN101952274A (zh)	2007-11-20	2011-01-19	默沙东公司	非核苷逆转录酶抑制剂
SI2924034T1 (sl) *	2010-03-30	2017-05-31	Merck Canada Inc.	Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze

2011
- 2011-03-28 SI SI201131054A patent/SI2924034T1/sl unknown
- 2011-03-28 MX MX2012011379A patent/MX2012011379A/es active IP Right Grant
- 2011-03-28 BR BR112012024691-7A patent/BR112012024691B1/pt active IP Right Grant
- 2011-03-28 PH PH1/2012/501923A patent/PH12012501923A1/en unknown
- 2011-03-28 LT LTEP15157348.2T patent/LT2924034T/lt unknown
- 2011-03-28 EP EP11761856.1A patent/EP2552902B1/en active Active
- 2011-03-28 PT PT117618561T patent/PT2552902E/pt unknown
- 2011-03-28 CN CN201180018074.2A patent/CN102971308B/zh active Active
- 2011-03-28 WO PCT/CA2011/000320 patent/WO2011120133A1/en not_active Ceased
- 2011-03-28 HU HUE11761856A patent/HUE025336T2/en unknown
- 2011-03-28 PL PL11761856T patent/PL2552902T3/pl unknown
- 2011-03-28 PL PL15157348T patent/PL2924034T3/pl unknown
- 2011-03-28 DK DK11761856.1T patent/DK2552902T3/en active
- 2011-03-28 PE PE2012001823A patent/PE20130158A1/es active IP Right Grant
- 2011-03-28 ME MEP-2015-76A patent/ME02181B/me unknown
- 2011-03-28 RS RS20150340A patent/RS54017B1/sr unknown
- 2011-03-28 SI SI201130491T patent/SI2552902T1/sl unknown
- 2011-03-28 EA EA201290976A patent/EA024804B1/ru active Protection Beyond IP Right Term
- 2011-03-28 ES ES15157348.2T patent/ES2609636T3/es active Active
- 2011-03-28 MY MYPI2012004342A patent/MY163979A/en unknown
- 2011-03-28 GE GEAP201112882A patent/GEP20156368B/en unknown
- 2011-03-28 DK DK15157348.2T patent/DK2924034T3/en active
- 2011-03-28 ME MEP-2016-282A patent/ME02570B/me unknown
- 2011-03-28 KR KR1020127025733A patent/KR101421861B1/ko active Active
- 2011-03-28 NZ NZ602670A patent/NZ602670A/en unknown
- 2011-03-28 EP EP15157348.2A patent/EP2924034B1/en active Active
- 2011-03-28 HU HUE15157348A patent/HUE031785T2/en unknown
- 2011-03-28 SG SG2012072401A patent/SG184347A1/en unknown
- 2011-03-28 CA CA2794377A patent/CA2794377C/en active Active
- 2011-03-28 PT PT151573482T patent/PT2924034T/pt unknown
- 2011-03-28 ES ES11761856.1T patent/ES2536295T3/es active Active
- 2011-03-28 RS RS20161093A patent/RS55505B1/sr unknown
- 2011-03-28 MA MA35324A patent/MA34170B1/fr unknown
- 2011-03-28 AU AU2011235568A patent/AU2011235568B2/en active Active
- 2011-03-28 US US13/073,631 patent/US8486975B2/en active Active
- 2011-03-28 JP JP2012538161A patent/JP5281718B2/ja active Active
- 2011-03-28 HR HRP20150427TT patent/HRP20150427T1/hr unknown
- 2011-03-29 AR ARP110101028A patent/AR080859A1/es active IP Right Grant
- 2011-03-29 TW TW100110833A patent/TWI458719B/zh active
2012
- 2012-09-20 IL IL222030A patent/IL222030A/en active Protection Beyond IP Right Term
- 2012-09-20 TN TNP2012000455A patent/TN2012000455A1/en unknown
- 2012-09-27 HN HN2012002039A patent/HN2012002039A/es unknown
- 2012-09-28 DO DO2012000256A patent/DOP2012000256A/es unknown
- 2012-09-28 NI NI201200146A patent/NI201200146A/es unknown
- 2012-09-28 CL CL2012002744A patent/CL2012002744A1/es unknown
- 2012-10-01 CO CO12171897A patent/CO6630126A2/es active IP Right Grant
- 2012-10-01 EC ECSP12012201 patent/ECSP12012201A/es unknown
- 2012-10-01 CR CR20120503A patent/CR20120503A/es unknown
2013
- 2013-05-23 JP JP2013108533A patent/JP5886790B2/ja not_active Expired - Fee Related
- 2013-07-03 US US13/934,633 patent/US20130296382A1/en not_active Abandoned
2014
- 2014-06-23 IL IL233334A patent/IL233334A/en active IP Right Grant
2016
- 2016-12-09 HR HRP20161680TT patent/HRP20161680T1/hr unknown
2017
- 2017-01-25 CY CY20171100114T patent/CY1118774T1/el unknown
2019
- 2019-04-09 HU HUS1900022C patent/HUS1900022I1/hu unknown
- 2019-04-09 HU HUS1900021C patent/HUS1900021I1/hu unknown
- 2019-04-11 LT LTPA2019507C patent/LTC2924034I2/lt unknown
- 2019-04-11 LT LTPA2019506 patent/LTC2552902I2/lt unknown
- 2019-04-16 NL NL300980C patent/NL300980I2/nl unknown
- 2019-04-17 FI FIC20190021C patent/FIC20190021I1/fi unknown
- 2019-04-17 LU LU00113C patent/LUC00113I9/fr unknown
- 2019-04-17 LU LU00114C patent/LUC00114I2/fr unknown
- 2019-04-24 NO NO2019019C patent/NO2019019I1/no unknown
- 2019-04-24 NO NO2019018C patent/NO2019018I1/no unknown
- 2019-05-16 CY CY2019026C patent/CY2019026I1/el unknown
- 2019-05-16 CY CY2019025C patent/CY2019025I1/el unknown

Also Published As

Publication number	Publication date
DK2924034T3 (en)	2017-02-06
CA2794377A1 (en)	2011-10-06
WO2011120133A1 (en)	2011-10-06
EP2552902B1 (en)	2015-03-11
SI2552902T1 (sl)	2015-10-30
HUS1900021I1 (hu)	2019-05-28
NL300980I1 (nl)	2019-04-24
EA024804B1 (ru)	2016-10-31
KR20120128703A (ko)	2012-11-27
GEP20156368B (en)	2015-09-25
AR080859A1 (es)	2012-05-16
PT2924034T (pt)	2017-01-06
MX2012011379A (es)	2012-11-30
DK2552902T3 (en)	2015-06-15
NZ602670A (en)	2014-09-26
CL2012002744A1 (es)	2012-12-14
CA2794377C (en)	2015-06-16
EP2552902A1 (en)	2013-02-06
PH12012501923A1 (en)	2013-02-04
US20130296382A1 (en)	2013-11-07
HK1209121A1 (en)	2016-03-24
HN2012002039A (es)	2015-08-24
US20110245296A1 (en)	2011-10-06
CY2019026I2 (el)	2020-05-29
HUE031785T2 (en)	2017-08-28
EP2924034A1 (en)	2015-09-30
IL233334A (en)	2015-09-24
HUS1900022I1 (hu)	2019-05-28
EA201290976A1 (ru)	2013-03-29
NL300980I2 (nl)	2021-06-17
NO2019019I1 (no)	2019-04-24
PE20130158A1 (es)	2013-02-28
KR101421861B1 (ko)	2014-07-22
CO6630126A2 (es)	2013-03-01
CN102971308B (zh)	2015-02-04
DOP2012000256A (es)	2012-12-15
CN102971308A (zh)	2013-03-13
CY2019025I2 (el)	2019-11-27
PL2552902T3 (pl)	2015-10-30
HRP20150427T1 (hr)	2015-07-03
RS55505B1 (sr)	2017-05-31
LTC2924034I2 (lt)	2020-10-12
BR112012024691B1 (pt)	2020-11-17
LT2924034T (lt)	2016-12-27
RS54017B1 (sr)	2015-10-30
EP2552902A4 (en)	2013-09-04
LUC00113I9 (2)	2024-06-07
JP5281718B2 (ja)	2013-09-04
CY2019025I1 (el)	2019-11-27
TW201139409A (en)	2011-11-16
ECSP12012201A (es)	2012-10-30
AU2011235568A1 (en)	2012-11-01
PT2552902E (pt)	2015-06-02
LUC00114I2 (2)	2020-07-10
HRP20161680T1 (hr)	2017-01-27
IL233334A0 (en)	2014-09-01
SG184347A1 (en)	2012-11-29
AU2011235568B2 (en)	2013-09-12
SI2924034T1 (sl)	2017-05-31
PL2924034T3 (pl)	2017-07-31
JP5886790B2 (ja)	2016-03-16
ES2536295T3 (es)	2015-05-22
ME02570B (me)	2017-06-20
LTPA2019506I1 (lt)	2019-04-25
HUE025336T2 (en)	2016-03-29
BR112012024691A2 (pt)	2019-07-02
HK1175471A1 (en)	2013-07-05
LUC00113I2 (2)	2024-05-22
IL222030A (en)	2014-07-31
JP2013209405A (ja)	2013-10-10
CR20120503A (es)	2013-01-09
NO2019018I1 (no)	2019-04-24
LUC00114I1 (2)	2019-04-17
EP2924034B1 (en)	2016-11-02
MY163979A (en)	2017-11-15
NI201200146A (es)	2013-03-18
FIC20190021I1 (fi)	2019-04-17
LTC2552902I2 (lt)	2019-12-10
TWI458719B (zh)	2014-11-01
TN2012000455A1 (en)	2014-01-30
LTPA2019507I1 (lt)	2019-04-25
CY1118774T1 (el)	2017-07-12
JP2013510800A (ja)	2013-03-28
MA34170B1 (fr)	2013-04-03
CY2019026I1 (el)	2020-05-29
ES2609636T3 (es)	2017-04-21
US8486975B2 (en)	2013-07-16

Publication	Publication Date	Title
ME02181B (me)	2015-10-20	Ne-nukleozidni inhibitori reverzne transkriptaze
HRP20180791T1 (hr)	2018-09-07	Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
ME02855B (me)	2018-04-20	KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI
HRP20200648T1 (hr)	2020-07-10	Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20220502T1 (hr)	2022-05-27	Kombinacije koje sadrže derivate 5-fenoksi-3h-pirimidin-4-ona i njihova uporaba za profilaksu ili liječenje infekcije hiv-om
JP2015504081A5 (2)	2016-03-10
HRP20210212T1 (hr)	2021-07-09	Triciklični spoj kao antikancerogeni agensi
HRP20200538T1 (hr)	2020-07-10	Derivati pirimidina za liječenje virusnih infekcija
HRP20210813T1 (hr)	2021-06-25	Piridinonpiridinilni spojevi supstituirani s metil/fluorpiridinilmetoksi i piridinonpiridinilni spojevi supstituirani s fluorpirimidinilmetoksi
HRP20170654T1 (hr)	2017-06-30	Makrociklički deaza-purinoni za liječenje virusnih infekcija
HRP20161125T1 (hr)	2016-11-18	Makrociklički purini za liječenje virusnih infekcija
ME02875B (me)	2018-04-20	Inhibitori hcv polimeraze
JP2018528946A5 (2)	2019-10-24
HRP20130976T1 (hr)	2013-11-22	Karbonilaminopirolopirazoli, potentni inhibitori kinaza
JP2019509276A5 (2)	2020-03-26
HRP20221495T1 (hr)	2023-02-03	Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita
RU2014141579A (ru)	2016-05-27	Гетероциклические соединения в качестве ингибиторов бета-лактамаз
ME02373B (me)	2016-06-20	Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze
CL2013003647A1 (es)	2014-07-04	Compuestos derivados de pirrolo[2,3-d] pirimidina o pirrolo[2,3-b]piridina, inhibidores de la actividad de jak; composicion farmaceutica; utiles para el tratamiento de enfermedades autoinmunitarias, inflamatorias y de reabsorcion osea, cancer, trastornos mieloproliferativos o rechazo a trasplante de organos.
HRP20211762T1 (hr)	2022-02-18	Derivati benzoksaborola za liječenje bakterijskih infekcija
MX385731B (es)	2025-03-18	Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
HRP20240937T1 (hr)	2024-10-25	Heteroaril spoj sa kondeziranim prstenom i njihova primjena kao trk inhibitora
AR078157A1 (es)	2011-10-19	Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
HRP20221207T1 (hr)	2022-12-09	Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5
JP2017527532A5 (2)	2018-08-16